STAR LABA biological mechanism is a starting point, not proof of treatment benefit.
β-Caryophyllene and CB2
Gertsch and colleagues reported in 2008 that β-caryophyllene activates CB2 receptors. Their work included laboratory experiments involving human cells and an inflammation model in mice. The mouse response depended on the presence of CB2. Human cells in a laboratory are not the same as a clinical trial in patients. [1]
A more recent clinical example
A December 2025 randomised multicentre study analysed 174 patients after surgery for chronic rhinosinusitis with nasal polyps. Adding defined eucalyptol–limonene–pinene enteric capsules to intranasal corticosteroids improved certain clinical measures compared with corticosteroids alone; the paper also reports inflammatory biomarker findings in a subgroup. This is evidence about a particular medicine, condition and combined treatment. [2]
Keep the two evidence levels distinct
| Research | What it supports | What it does not establish |
|---|---|---|
| CB2 experiments | A plausible mechanism and preclinical response. | A proven general anti-inflammatory treatment in humans. |
| Post-surgery clinical trial | Benefits of a specified combination in the studied patient group. | Benefits from isolated limonene, cannabis flower or live rosin. |
What belongs in a professional profile
Record the compound, study model, tested preparation, comparator and outcome. Do not assign an “anti-inflammatory” product badge solely because β-caryophyllene appears on a report. The relevant next question is whether the same preparation has credible clinical evidence for the same condition. No PSL product was tested in the cited papers.
Sources & further reading
- Gertsch et al. (2008), PNAS — Beta-caryophyllene is a dietary cannabinoid
- Sima et al. (2025), Clinical and Translational Allergy — Eucalyptol, limonene and pinene capsules after sinus surgery
Research findings and public-agency definitions are attributed above. Reading checklists are editorial guidance, not laboratory findings.